Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 104, Issue 23, 2012, Pages 1808-1814

  Sahasrabuddhe, Vikrant V ^a   Gunja, Munira Z ^a   Graubard, Barry I ^a   Trabert, Britton ^a   Schwartz, Lauren M ^a   Park, Yikyung ^a   Hollenbeck, Albert R ^b   Freedman, Neal D ^a   Mcglynn, Katherine A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AARP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EXCEDRIN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; ROFECOXIB; SULINDAC;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG UTILIZATION; ETHNIC DIFFERENCE; FEMALE; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SMOKING;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COMORBIDITY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INCIDENCE; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84870858674     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs452     Document Type: Article

References (31)

1. Jemal A, Bray F, Center M.M., et al Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. McGlynn KA, London WT The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223-423, vii-x.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12): 1118-1127.
4. Altekruse SF, McGlynn KA, Reichman ME Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491.
5. Spangenberg HC, Thimme R, Blum HE Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008;2(3):425-433.
6. Yang JD, Roberts LR Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448-458.
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
8. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol. 2006;12(32):5113-5121.
9. Weber A, Boege Y, Reisinger F., et al Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med Wkly. 2011;141:w13197.
10. Cuzick J, Otto F, Baron J.A., et al Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501-507.
11. Langley RE, Burdett S, Tierney J.F., et al Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107-1113.
12. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32(6):1491-1502.
13. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res. 2009;181:231-251.
14. Luo T, Yan HM, He P, et al Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2012;131(2):581-587.
15. Rothwell PM, Fowkes FG, Belch J.F., et al Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
16. Liao LM, Vaughan TL, Corley D.A., et al Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophago-gastric junction in a pooled analysis. Gastroenterology. 2012;142(3):442-452 e5; quiz e22-23.
17. Bosetti C, Rosato V, Gallus S., Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403-1415.
18. Chan AT, Arber N, Burn J., et al Aspirin in the chemoprevention of colo-rectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5(2):164-178.
19. Fodera D, D'Alessandro N, Cusimano A, et al Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci. 2004;1028(1):440-449.
20. Leng J, Han C, Demetris A.J., et al Cyclooxygenase-2 promotes hepato-cellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38(3):756-768.
21. Cervello M, Foderaa D, Florena A.M., et al Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol. 2005;11(30):4638-4643.
22. Coogan PF, Rosenberg L, Palmer J.R., et al Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 2000;9(1):119-123.
23. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997;40(9):1580-1586.
24. Schatzkin A, Subar AF, Thompson F.E., et al Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001;154(12):1119-1125.
25. Knights KM, Mangoni AA, Miners JO Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol. 2010;3(6):769-776.
26. Jankowska H, Hooper P, Jankowski JA Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review of the evidence. Pol Arch Med Wewn. 2010;120(10):407-412.
27. Kern MA, Schubert D, Sahi D., et al Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology. 2002;36(4 Pt 1):885-894.
28. Imaeda AB, Watanabe A, Sohail M.A., et al Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009;119(2):305-314.
29. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol. 2008;48(2):380-381.
30. Tsan YT, Lee CH, Wang J.D., et al Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623-630.
31. Valkhoff VE, Sturkenboom MC, Kuipers EJ Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26(2):125-140.